source
- Arrowhead reports Phase 3 data showing potentially best-in-class triglyceride reduction, eyes FDA filingArrowhead Pharmaceuticals announced topline results from two late-stage Phase 3 trials (SHASTA-3 and SHASTA-4) of its siRNA drug plozasiran in patients with severe hypertriglyceridemia (sHTG). Th…
- Congressional panel warns US rare-disease lead is eroding and calls for supportive policiesA Congressional advisory panel has urged the U.S. government to adopt policies that would help rare disease drug development, including a finalized FDA platform designation and the use of novel tri…